AbbVie’s Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

May saw a drug ad spending slump across the majority of the top ten drug ad spenders with AbbVie’s Skyrizi and RInvoq, Johnson & Johnson’s

Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.

EVERSANA has named Jen Norton as president of its recently formed Market Access & Value division.